Dermazene Disease Interactions

Percutaneous absorption of iodoquinol topical has not been characterized, however, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. The use of oral iodoquinol therapy is contraindicated in patients with hepatic disease.

Switch to professional interaction data

Percutaneous absorption of iodoquinol topical has not been characterized, however, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. The following thyroid abnormalities may occur during oral iodoquinol therapy: protein-bound serum iodine levels may be increased during treatment with iodoquinol resulting in alteration of certain thyroid function tests. Therapy with iodoquinol should be administered cautiously to patients with thyroid disease.

Switch to professional interaction data

Percutaneous absorption of iodoquinol topical has not been characterized. However, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. The following visual field defects have occurred during oral iodoquinol therapy: optic neuritis and optic atrophy when given in high dosages for prolonged periods. Optic atrophy has been reported mostly in children treated for acrodermatitis enteropathica at daily dosages between 1300 to 3600 mg for up to two years. Visual deterioration may be irreversible. Therapy with iodoquinol should be administered cautiously in patients with or predisposed to visual defects. Some clinicians also recommend not using iodoquinol and related agents in pediatric patients under 12 years of age. Long-term therapy should be avoided in all patients.

Switch to professional interaction data

Percutaneous absorption of iodoquinol topical has not been characterized, however, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. Peripheral neuropathies may occur during oral iodoquinol therapy. Therapy with iodoquinol topical should be administered cautiously in patients with peripheral neuropathy.

Switch to professional interaction data

Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia. Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration. Use of occlusive dressings over the applied areas may also increase percutaneous absorption. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.

Switch to professional interaction data

Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing's syndrome and intracranial hypertension because of their larger skin surface to body mass ratios. If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.

Switch to professional interaction data

The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism. Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression. Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Patients with an altered skin barrier or liver failure are also at increased risk. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.

Switch to professional interaction data

Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios. Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used. Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection. If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults. Occlusive dressings should not be used in patients with skin infection.

Switch to professional interaction data

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area. Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used. Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.

Switch to professional interaction data